Market Intelligence, Clinical Progress, and High-Purity Reagents for Cell Cycle-Directed Oncology Development.
CCND1 (Cyclin D1) is a key regulator of the G1/S cell cycle transition, characterized by a Cyclin N-terminal domain (UniProt P24385). It forms complexes with CDK4 and CDK6 to drive cell proliferation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCND1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCND1 Recombinant Protein (Wild-type & T286A Mutant); also available as CCND1-CDK4 Heterodimer Complex. >95% purity, Endotoxin <1EU/μg, Sequence Verified. HEK293 expressed, theoretical MW validated. | View CCND1 Products |
| Gene Delivery | CCND1 Lentivirus Premade Particles / Promise-ORF. Full-length ORF for stable cell line generation. Sequence Verified. | View CCND1 Products |
| Benchmark Ab | Anti-CCND1 Recombinant Antibody. Sequence-verified positive control for Western blot and IHC. | View CCND1 Products |
| Validator | CCND1 siRNA Set (3 unique sequences). For knockdown verification and specificity checks. | View CCND1 Products |
| Related Target: CDK4 | Direct binding partner for CCND1 complex formation and kinase activity assays. | View CDK4 Products |
| Related Target: CDK6 | Alternative kinase partner; focus on hematopoietic malignancies and pathway selectivity studies. | View CDK6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (PROTACs) | High-purity full-length CCND1 protein (>95%) for accurate SPR/BLI binding kinetics; verified stability for ternary complex assays. |
| Kinase Activity Reconstitution | Sequence Verified wild-type and mutant proteins (T286A, Y44D) for in vitro functional reconstitution with CDK4/6. |
| CDK4/6 Selectivity Profiling | Purified CCND1-CDK4 and CCND1-CDK6 heterodimer complexes; also homolog panel (CCND2, CCND3) for off-target screening. |
| Resistance Mechanism Evaluation (RB1 loss, CCNE1 amplification) | Related protein panel: RB1 and CCNE1 available for combination studies. |
| Lack of Controls / False Positives | Validated siRNA and recombinant antibodies included for specificity checks in cellular degradation assays. |
| Resistance Mutation Analysis (T286A, Y44D) | Pre-made mutant recombinant proteins; mass spec verified. |
Live CCND1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for CCND1-directed therapeutics is transitioning from indirect targeting (via CDK4/6 inhibitors) to direct modulation through targeted protein degradation (PROTACs and molecular glues) and protein-protein interaction inhibitors. First-generation CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) face acquired resistance in the clinic, driven by mechanisms such as RB1 loss, CCNE1 amplification, and CCND1 mutations (e.g., T286A). The next wave of R&D focuses on degraders that eliminate CCND1 protein entirely, bypassing kinase-independent oncogenic functions. Combination strategies with endocrine therapy (e.g., fulvestrant, oral SERDs) and PI3K/AKT/mTOR inhibitors are also advancing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CDK4/6 Inhibitors (Small Molecule) | Pfizer, Novartis, Eli Lilly | HR+ Breast Cancer, Mantle Cell Lymphoma | Cell-free kinase assay; need high-purity CCND1-CDK4/6 complex proteins for binding kinetics and selectivity panels (wild-type vs mutant). |
| PROTAC Degraders | Arvinas, Kymera, C4 Therapeutics | Solid Tumors (Breast, Lung), MCL | Ternary complex formation assay; need full-length CCND1 (wild-type and mutant) and E3 ligase proteins. |
| Molecular Glues | Emerging Biotechs | Multiple Myeloma, AML | PPI interface mapping with purified CCND1-CDK4/6 complexes; disruptor selectivity screening. |
| Peptide / Macrocycle Inhibitors | Academic and biotech pipelines | Mantle Cell Lymphoma, Solid Tumors | PPI disruption assay; need full-length CCND1 (>95% pure) and CDK4/6 partners. |
| RNAi / Antisense | Alnylam, Ionis | Refractory Cancers | Knockdown validation; need CCND1 siRNA and lentiviral ORF rescue constructs. |